Previous Article | Next Article ![]()
Infection and Immunity, August 1999, p. 4128-4133, Vol. 67, No. 8
Department of Immunology,
Received 5 March 1999/Returned for modification 4 May 1999/Accepted 17 May 1999
Host defenses against Streptococcus pneumoniae depend
largely on opsonophagocytosis mediated by antibodies and complement. Since pneumococcus is a respiratory pathogen, mucosal immune responses may play a significant role in the defense against pneumococcal infections. Thus, mucosal vaccination may be an alternative approach to
current immunization strategies, but effective adjuvants are required.
Protein antigens induce significant mucosal immunoglobulin A (IgA) and
systemic IgG responses when administered intranasally (i.n.) with the
glyceride-polysorbate based adjuvant RhinoVax (RV) both in experimental
animals and humans. The immunogenicity and efficacy of pneumococcal
polysaccharide conjugate vaccines (PNC) of serotypes 1 and 3 was
studied in mice after i.n. immunization with RV. Antibodies were
measured in serum (IgM, IgG, and IgA) and saliva (IgA) and compared to
antibody titers induced by parenteral immunization. The PNCs induced
significant systemic IgG and IgA antibodies after i.n. immunization
only when given with RV and, for serotype 1, serum IgG titers were
comparable to titers induced by subcutaneous immunization. In addition,
i.n. immunization with PNC-1 in RV elicited detectable mucosal IgA.
These results demonstrate that RV is a potent mucosal adjuvant for
polysaccharides conjugated to proteins. A majority of the
PNC-1-immunized mice were protected against both bacteremia and
pneumonia after i.n. challenge with a lethal dose of serotype 1 pneumococci, and protection correlated significantly with the serum IgG
titers. Similarly, the survival of mice immunized i.n. with PNC-3 in RV
was significantly prolonged. These results indicate that mucosal
vaccination with PNC and adjuvants may be an alternative strategy for
prevention against pneumococcal infections.
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Intranasal Immunization with Pneumococcal
Polysaccharide Conjugate Vaccines Protects Mice against Invasive
Pneumococcal Infections
*
Corresponding author. Mailing address: Ingileif
Jónsdóttir, Department of Immunology, National University
Hospital, 101 Reykjavik, Iceland. Phone: 354-560-1962. Fax:
354-560-1943. E-mail: ingileif{at}rsp.is.
Infection and Immunity, August 1999, p. 4128-4133, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»